Objective: The primary objective of this pilot study was to demonstrate the benefits of topical human platelet extract (plated)™ serum for the improvement of persistent facial redness.
Methods: This single-center, open-label pilot study evaluated six subjects using (plated)™ serum containing human platelet extract (HPE) with Renewosome™ technology twice daily for six weeks. The primary efficacy endpoint was a reduction in the Clinical Erythema Assessment (CEA) grade, and a reduction in Patient Subjective Assessment grade at six weeks. Secondary endpoints included an improvement in quality of life related to facial redness, and a reduction in redness by Mexameter™ spectrometry measurement. Safety data included monitoring for adverse events.
Results: Topical HPE serum demonstrated a statistically significant improvement in facial redness at Week 9 when averaging the Mexameter™ spectrometry results across nine regions of the face (=0.0052). The primary and secondary endpoints were achieved. CEA grade at Week 6 demonstrated that all subjects improved by at least one grade, while one subject improved by two grades. One patient reported dryness. No other adverse effects were observed.
Limitations: Study limitations included a small sample size and lack of darker skin types (Fitzpatrick IV-VI).
Conclusion: This study demonstrates that topical HPE with Renewosome™ technology provides statistically significant reduction in facial redness and is safe and well-tolerated.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617900 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Clinical characteristics and serological profiles of Lyme disease in children: a 15-year retrospective cohort study in Switzerland.
Lancet Reg Health Eur
January 2025
Division of Infectious Diseases and Hospital Epidemiology, Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
Background: Lyme disease (LD) is caused by and is the most common tickborne disease in the northern hemisphere. Although classical characteristics of LD are well-known, the diagnosis and treatment are often delayed. Laboratory diagnosis by serological testing is recommended for most LD manifestations.
View Article and Find Full Text PDFClinical and Dermoscopic Evaluation of Patients With Topical Steroid Damaged Faces (TSDF).
Cureus
November 2024
Dermatology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Ambala, IND.
Background Topical steroid-dependent or damaged face (TSDF) is a common condition where the widespread availability of over-the-counter topical corticosteroid (TCS)-containing products leads to their misuse and addiction. Prolonged use of these steroids on the face can result in significant side effects. Early diagnosis and cessation of steroid use are important.
View Article and Find Full Text PDFAn alternative multidrug regimen for multibacillary Hansen's disease: a case report.
J Med Case Rep
December 2024
Division of Infectious Diseases, Denver Health Medical Center, Denver, CO, USA.
Background: Leprosy (Hansen's disease) is an infectious disease most common in resource-limited countries caused by the acid-fast bacilli Mycobacterium leprae and Mycobacterium lepromatosis that frequently affects the skin and peripheral nerves. Prompt diagnosis and treatment with multidrug therapy is crucial to reduce disease transmission and sequelae, which include nerve function impairment, ocular injury, and stigmatizing physical deformities. Traditional treatment of multibacillary leprosy consists of 12-24 months of multidrug therapy with dapsone, rifampin, and clofazimine.
View Article and Find Full Text PDFThe Therapeutic Potential of Oral Everolimus for Facial Angiofibromas in Pediatric Tuberous Sclerosis Complex: A Case-Based Analysis of Efficacy.
Diseases
December 2024
Department of Pediatrics, Dokkyo Medical University, Tochigi 321-0293, Japan.
Background: Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder characterized by mutations in the TSC1 and TSC2 genes, leading to the dysregulation of the mammalian target of rapamycin (mTOR) pathway. This dysregulation results in the development of benign tumors across multiple organ systems and poses significant neurodevelopmental challenges. The clinical manifestations of TSC vary widely and include subependymal giant cell astrocytomas (SEGAs), renal angiomyolipomas (AMLs), facial angiofibromas (FAs), and neuropsychiatric conditions such as autism spectrum disorder (ASD).
View Article and Find Full Text PDFVenom-spit ophthalmia: A novel envenomation of Monocled Cobra (Naja kaouthia).
Toxicon
December 2024
Venom Research Centre, Chittagong Medical College, Chattogram-4203, Bangladesh; Department of Zoology, University of Chittagong, Chattogram-4331, Bangladesh.
Handling venomous snakes poses a significant risk of envenomation. In the case of spitting cobras, additional precautions, like wearing face shields, are necessary to prevent ophthalmic envenomation. Although, the Monocled Cobra (Naja kaouthia) is not a true spitting cobra, however some spitting events has been reported from Northeastern India and Nepal but ocular envenomation is scarce.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!